Valenti L - Search Results

1

CD47-SIRPα axis blockade in NASH promotes necroptotic hepatocyte clearance by liver macrophages and decreases hepatic fibrosis.

Shi H, Wang X, Li F, Gerlach BD, Yurdagul A Jr, Moore MP, Zeldin S, Zhang H, Cai B, Zheng Z, Valenti L, Tabas I. Shi H, et al. Among authors: valenti l. Sci Transl Med. 2022 Nov 23;14(672):eabp8309. doi: 10.1126/scitranslmed.abp8309. Epub 2022 Nov 23. Sci Transl Med. 2022. PMID: 36417485 Free PMC article.

2

Serum hyaluronic acid for the screening of progressive nonalcoholic steatohepatitis in children: a promising approach.

Valenti L, Dongiovanni P. Valenti L, et al. Transl Res. 2010 Oct;156(4):226-8. doi: 10.1016/j.trsl.2010.06.004. Epub 2010 Jul 8. Transl Res. 2010. PMID: 20875898

3

Risk of nonalcoholic steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease and low visceral adiposity.

Fracanzani AL, Valenti L, Bugianesi E, Vanni E, Grieco A, Miele L, Consonni D, Fatta E, Lombardi R, Marchesini G, Fargion S. Fracanzani AL, et al. Among authors: valenti l. J Hepatol. 2011 Jun;54(6):1244-9. doi: 10.1016/j.jhep.2010.09.037. Epub 2010 Nov 11. J Hepatol. 2011. PMID: 21145841 Free article.

4

Genetic predisposition in NAFLD and NASH: impact on severity of liver disease and response to treatment.

Dongiovanni P, Anstee QM, Valenti L. Dongiovanni P, et al. Among authors: valenti l. Curr Pharm Des. 2013;19(29):5219-38. doi: 10.2174/13816128113199990381. Curr Pharm Des. 2013. PMID: 23394097 Free PMC article.

5

Hepatic notch signaling correlates with insulin resistance and nonalcoholic fatty liver disease.

Valenti L, Mendoza RM, Rametta R, Maggioni M, Kitajewski C, Shawber CJ, Pajvani UB. Valenti L, et al. Diabetes. 2013 Dec;62(12):4052-62. doi: 10.2337/db13-0769. Epub 2013 Aug 29. Diabetes. 2013. PMID: 23990360 Free PMC article.

6

Dietary anthocyanins as nutritional therapy for nonalcoholic fatty liver disease.

Valenti L, Riso P, Mazzocchi A, Porrini M, Fargion S, Agostoni C. Valenti L, et al. Oxid Med Cell Longev. 2013;2013:145421. doi: 10.1155/2013/145421. Epub 2013 Oct 24. Oxid Med Cell Longev. 2013. PMID: 24282628 Free PMC article. Review.

7

Genetics of nonalcoholic fatty liver disease.

Dongiovanni P, Valenti L. Dongiovanni P, et al. Among authors: valenti l. Metabolism. 2016 Aug;65(8):1026-37. doi: 10.1016/j.metabol.2015.08.018. Epub 2015 Sep 1. Metabolism. 2016. PMID: 26409295 Review.

8

MERTK rs4374383 polymorphism affects the severity of fibrosis in non-alcoholic fatty liver disease.

Petta S, Valenti L, Marra F, Grimaudo S, Tripodo C, Bugianesi E, Cammà C, Cappon A, Di Marco V, Di Maira G, Dongiovanni P, Rametta R, Gulino A, Mozzi E, Orlando E, Maggioni M, Pipitone RM, Fargion S, Craxì A. Petta S, et al. Among authors: valenti l. J Hepatol. 2016 Mar;64(3):682-90. doi: 10.1016/j.jhep.2015.10.016. Epub 2015 Oct 24. J Hepatol. 2016. PMID: 26596542 Free article.

9

Liver fat accumulation is associated with circulating PCSK9.

Ruscica M, Ferri N, Macchi C, Meroni M, Lanti C, Ricci C, Maggioni M, Fracanzani AL, Badiali S, Fargion S, Magni P, Valenti L, Dongiovanni P. Ruscica M, et al. Among authors: valenti l. Ann Med. 2016 Aug;48(5):384-91. doi: 10.1080/07853890.2016.1188328. Epub 2016 May 25. Ann Med. 2016. PMID: 27222915

10

Renin-Angiotensin System Inhibitors, Type 2 Diabetes and Fibrosis Progression: An Observational Study in Patients with Nonalcoholic Fatty Liver Disease.

Pelusi S, Petta S, Rosso C, Borroni V, Fracanzani AL, Dongiovanni P, Craxi A, Bugianesi E, Fargion S, Valenti L. Pelusi S, et al. Among authors: valenti l. PLoS One. 2016 Sep 20;11(9):e0163069. doi: 10.1371/journal.pone.0163069. eCollection 2016. PLoS One. 2016. PMID: 27649410 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

563 results

Search Page